دورية أكاديمية
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments.
| العنوان: | Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments. |
|---|---|
| المؤلفون: | Geethakumari PR; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 2201 Inwood Road, Dallas, TX, 76034, USA., Ramasamy DP; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 2201 Inwood Road, Dallas, TX, 76034, USA., Dholaria B; Vanderbilt University Medical Center, Nashville, TN, USA., Berdeja J; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA., Kansagra A; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 2201 Inwood Road, Dallas, TX, 76034, USA. ankit.kansagra@utsouthwestern.edu. |
| المصدر: | Current hematologic malignancy reports [Curr Hematol Malig Rep] 2021 Aug; Vol. 16 (4), pp. 345-356. Date of Electronic Publication: 2021 Jun 05. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Current Science Country of Publication: United States NLM ID: 101262565 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-822X (Electronic) Linking ISSN: 15588211 NLM ISO Abbreviation: Curr Hematol Malig Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, Pa. : Current Science, c2006- |
| مواضيع طبية MeSH: | Drug Delivery Systems/*methods , Immunotherapy/*methods , Neoplasms/*economics , Neoplasms/*therapy, Humans |
| مستخلص: | Purpose of Review: The chimeric antigen receptor (CAR) T-cell therapy is currently changing the landscape of hematologic malignancies with multiple FDA-approved cell therapy products in the USA. The current administration process of the CAR T-cell therapy is complicated, labor-intensive, and expensive. Recent Findings: The chimeric antigen receptor (CAR) T-cell therapy is currently changing the landscape of hematologic malignancies with multiple FDA-approved cell therapy products in the USA. The current administration process of the CAR T-cell therapy is complicated, labor-intensive, and expensive. This review article addresses the present-day challenges and discusses opportunities to optimize the access and affordability of the CAR T-cell therapy. The field of cellular immunotherapy is going to change the future of solid tumors and non-oncological diseases. However, this promising therapy poses challenges in the administration and management of quality in the current field of healthcare. We describe various novel approaches to manage challenges in improving access and improving widescale implementation of cellular therapies. (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| References: | Curr Hematol Malig Rep. 2015 Sep;10(3):199-204. (PMID: 26003329) Blood Adv. 2020 Feb 25;4(4):629-637. (PMID: 32074277) Lancet. 2020 Sep 19;396(10254):839-852. (PMID: 32888407) J Clin Oncol. 2021 Feb 10;39(5):456-466. (PMID: 33434058) Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):579-584. (PMID: 33275680) Oncologist. 2020 Jul;25(7):e1117-e1119. (PMID: 32386072) Bone Marrow Transplant. 2020 Sep;55(9):1706-1715. (PMID: 32474570) Cells. 2020 May 27;9(6):. (PMID: 32471151) Nat Rev Immunol. 2020 Nov;20(11):651-668. (PMID: 32433532) J Clin Oncol. 2018 Nov 10;36(32):3192-3202. (PMID: 30212291) J Clin Oncol. 2020 Sep 20;38(27):3095-3106. (PMID: 32667831) J Clin Oncol. 1999 Sep;17(9):2811-8. (PMID: 10561357) J Clin Oncol. 2019 Aug 20;37(24):2105-2119. (PMID: 31157579) AMA J Ethics. 2019 Oct 1;21(10):E844-851. (PMID: 31651383) N Engl J Med. 2018 Feb 1;378(5):439-448. (PMID: 29385370) J Clin Oncol. 2020 Sep 20;38(27):3119-3128. (PMID: 32401634) N Engl J Med. 2018 Jul 5;379(1):64-73. (PMID: 29972754) J Geriatr Oncol. 2021 May;12(4):585-591. (PMID: 33162369) N Engl J Med. 2021 Feb 25;384(8):705-716. (PMID: 33626253) Biol Blood Marrow Transplant. 2020 Jan;26(1):34-43. (PMID: 31605820) Lancet Oncol. 2019 Jan;20(1):31-42. (PMID: 30518502) Biol Blood Marrow Transplant. 2019 May;25(5):e155-e162. (PMID: 30500439) J Immunother Cancer. 2017 Apr 18;5:36. (PMID: 28428885) Biol Blood Marrow Transplant. 2013 Apr;19(4):547-51. (PMID: 23253556) Blood. 2020 Jun 4;135(23):2020-2021. (PMID: 32497222) Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-8. (PMID: 32347759) JAMA Netw Open. 2020 Apr 1;3(4):e202072. (PMID: 32250433) Immunol Res. 2020 Feb;68(1):63-70. (PMID: 32096010) Proc Natl Acad Sci U S A. 2019 May 7;116(19):9543-9551. (PMID: 30988175) J Mark Access Health Policy. 2020 Jan 15;8(1):1715536. (PMID: 32082514) N Engl J Med. 2019 Jan 3;380(1):45-56. (PMID: 30501490) JAMA Netw Open. 2019 Feb 1;2(2):e190035. (PMID: 30794298) J Clin Oncol. 2018 Aug 1;36(22):2267-2280. (PMID: 29812997) Front Immunol. 2021 Jan 08;11:618427. (PMID: 33488631) N Engl J Med. 2010 Dec 23;363(26):2477-81. (PMID: 21142528) J Natl Cancer Inst. 2019 Jul 1;111(7):719-726. (PMID: 30551196) N Engl J Med. 2017 Dec 28;377(26):2531-2544. (PMID: 29226797) J Geriatr Oncol. 2021 Mar;12(2):239-242. (PMID: 32798213) N Engl J Med. 2020 Apr 2;382(14):1331-1342. (PMID: 32242358) J Clin Oncol. 2021 Feb 10;39(5):476-486. (PMID: 33434079) |
| فهرسة مساهمة: | Keywords: Access; Acute lymphoblastic leukemia; Barriers; CAR T cell therapy; Cost-effectiveness; Immune-effector cell therapy; Immunotherapy; Lymphoma; Multiple myeloma; Quality |
| تواريخ الأحداث: | Date Created: 20210605 Date Completed: 20210830 Latest Revision: 20230917 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8179081 |
| DOI: | 10.1007/s11899-021-00635-3 |
| PMID: | 34089485 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1558-822X |
|---|---|
| DOI: | 10.1007/s11899-021-00635-3 |